Stock comparison
Genmab A/S
Soleno Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
SLNO
Soleno Therapeutics
Market cap
$2.76B
Sector
Healthcare
Overall winner
Soleno Therapeutics SLNO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | SLNO | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 57C | GMAB |
| Benjamin Graham | 64C | 66D | SLNO |
| Philip Fisher | 48D | 69C | SLNO |
| Peter Lynch | 25F | 58C | SLNO |
| Joel Greenblatt | 76B | 62C | GMAB |
| Charlie Munger | 68C | 63D | GMAB |
| Terry Smith | 71C | 66B | GMAB |
Side-by-side metrics
| Metric | GMAB | SLNO |
|---|---|---|
| Market cap | $16.5B | $2.76B |
| P/E (TTM) | 6.2x | 28.7x |
| EV/EBIT | 12.0x | 176.1x |
| ROIC (TTM) | 43.78% | 15.35% |
| Gross margin | 93.88% | 98.63% |
| Net margin | 18.23% | 33.7% |
| Revenue CAGR 5y | -18.45% | - |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- EV/EBIT12.0xvs 176.1x+93%
- Market cap$16.5Bvs $2.76B+83%
- P/E (TTM)6.2xvs 28.7x+79%
- ROIC (TTM)43.78%vs 15.35%+65%
SLNO leads on
- Debt / Equity0.0xvs 0.1x+88%
- Net margin33.7%vs 18.23%+46%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.